ストックスクリーナーアプリを入手
1.28
0.78%
-0.01
前日終値:
$1.29
開ける：
$1.29
24時間の取引高:
738.76K
Relative Volume:
0.49
時価総額：
$319.10M
収益：
$14.78M
当期純損益:
$-64.01M
株価収益率:
-4.4553
EPS:
-0.2873
ネットキャッシュフロー:
$-22.59M
1週間 パフォーマンス:
-5.19%
1か月 パフォーマンス:
+4.07%
6か月 パフォーマンス:
-25.15%
1年 パフォーマンス:
+25.49%
1日の値動き範囲:
$1.25
$1.30
1週間の範囲:
$1.25
$1.38
52週間の値動き範囲:
$0.9296
$2.09
Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile
名前
Lineage Cell Therapeutics Inc
セクター
電話
510-871-4188
住所
2173 Salk Avenue, Suite 200, Carlsbad, CA
Compare LCTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LCTX
Lineage Cell Therapeutics Inc
|
1.28 | 319.10M | 14.78M | -64.01M | -22.59M | -0.2873 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-20 | 開始されました | Craig Hallum | Buy |
| 2022-11-02 | 開始されました | Robert W. Baird | Outperform |
| 2022-06-14 | 開始されました | B. Riley Securities | Buy |
| 2021-08-19 | 開始されました | Noble Capital Markets | Outperform |
| 2021-03-31 | 開始されました | Cantor Fitzgerald | Overweight |
Lineage Cell Therapeutics Inc (LCTX) 最新ニュース
Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit - BioSpace
Price to book forward of Lineage Cell Therapeutics, Inc. – AMEX:LCTX - TradingView
Price to sales forward of Lineage Cell Therapeutics, Inc. – AMEX:LCTX - TradingView
LCTX Q1 2026 Earnings: EPS Misses Estimates Despite Positive Stock ReactionShare Dilution Risk - dars.gov.et
LCTXLineage Cell Therapeutics Inc Stock Price and Quote - Finviz
Form 4 Lineage Cell Therapeutics Inc For: 2 July By Investing.com - Investing.com India
Lineage Cell (LCTX) director granted 125,000 options at $1.30 strike - Stock Titan
Lineage Cell Therapeutics (LCTX) director receives 125,000 stock options at $1.30 - Stock Titan
Lineage Cell Therapeutics (LCTX) director awarded 125,000 stock options at $1.30 - Stock Titan
Lineage Cell Therapeutics (LCTX) director granted 125,000 options at $1.30 strike - Stock Titan
Transcript: Lineage Cell Therapeutics Q1 2026 Earnings Conference Call - Benzinga
Lineage Cell Therapeutics, Inc.(NYSEAM:LCTX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Lineage Cell Therapeutics, Inc.(NYSEAM: LCTX) added to Russell 2000 Index - marketscreener.com
Lineage Cell Therapeutics, Inc.(NYSEAM: LCTX) added to Russell 2500 Growth Benchmark - marketscreener.com
Lineage Cell Therapeutics, Inc.(NYSEAM: LCTX) added to Russell 2000 Growth Benchmark - marketscreener.com
Lineage Cell Therapeutics, Inc.(NYSEAM: LCTX) added to Russell 3000E Index - marketscreener.com
Lineage Cell Therapeutics, Inc.(NYSEAM:LCTX) added to Russell 3000E Growth Benchmark - marketscreener.com
Lineage Cell Therapeutics, Inc.(NYSEAM:LCTX) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Price to book forward of Lineage Cell Therapeutics, Inc. – LSX:A2PP89 - TradingView
BT3 Forecast — Price Target — Prediction for 2027 - TradingView
Lineage Cell Therapeutics, Inc. Actuals & Estimates (TASE:LCTX) - TradingView
LCTX Holds Tight Range As Traders Eye Next Break - StocksToTrade
LCTX Edges Higher As Traders Focus On Tight Range Break - timothysykes.com
LCTX Edges Higher As Traders Focus On Tight Range Setup - StocksToTrade
LCTX Forecast — Price Target — Prediction for 2027 - TradingView
Lineage Cell Therapeutics, Inc. Actuals & Estimates (DUS:BT3) - TradingView
Lineage Cell Therapeutics Inc. (LCTX) Q1 2026 Earnings: EPS Miss Weighs on Pre-Revenue Biotech - dars.gov.et
Streamlined procurement and lean AP workflows drive efficiency at Lineage Cell Therapeutics - Traders Union
Enterprise value to EBITDA forward of Lineage Cell Therapeutics, Inc. – AMEX:LCTX - TradingView
Enterprise value to EBITDA forward of Lineage Cell Therapeutics, Inc. – LSX:A2PP89 - TradingView
Aardvark Therapeutics Leads The Charge With 2 Other Noteworthy Penny Stocks - simplywall.st
Lineage Cell Therapeutics Inc (LCTX) Institutional Confidence - TradingKey
LCTX Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Advances PipelineEarnings Expansion Phase - dars.gov.et
Lineage Cell Therapeutics Inc (LCTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lineage Cell Therapeutics (LCTX) Stock Faces Mixed Analyst Target Changes After Fresh Coverage - Yahoo Finance
Lineage Cell Therapeutics Inc (LCTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lineage Cell Therapeutics Inc (LCTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lineage Cell Therapeutics Inc (LCTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lineage Cell Therapeutics Inc (LCTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lineage Cell Therapeutics Inc (LCTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Lineage Cell Therapeutics Inc - TradingKey
Lineage Cell Therapeutics Inc (LCTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lineage Cell Therapeutics joins panel on novel treatments at Clinical Trials at the Summit - Traders Union
Lineage Cell Shareholders Reaffirm Governance and Executive Pay - The Globe and Mail
Lineage Cell (NYSE: LCTX) investors back board, say-on-pay as OPC1 grant bid withdrawn - Stock Titan
LCTX Q1 2026 Earnings: EPS Miss Reflects Ongoing R&D InvestmentTrough Earnings Signal - newsline.com
LCTX Q1 2026 Earnings: EPS Misses Estimates by 47% as Company Continues Clinical DevelopmentReturn On Assets - newsline.com
How The Lineage Cell Therapeutics (LCTX) Story Is Shifting With New Data And Analyst Targets - Yahoo Finance
LCTX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Lineage Cell Therapeutics (LCTX) price target increased by 14.58% to 5.61 - MSN
LCTX Q1 2026 Earnings: Wider Loss Than Expected Amid Ongoing Pipeline DevelopmentForward EPS Estimate - newsline.com
Lineage Cell Therapeutics Inc (LCTX) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):